Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung

A. Ardizzoni, L. Canobbio, P. Pronzato, A. Rubagotti, M. De Palma, F. Baracco, J. Serrano, S. Serrano, B. Faravelli, M. Nosenzo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Fifty patients with advanced squamous cell carcinoma and adenocarcinoma of the lung having good prognostic features (performance status ≤ 2; weight loss ≤ 10%; and age ≤ 70 years; absence of brain metastases; and no prior treatment) were treated on an outpatient basis with etoposide (120 mg/m2 on Days 1, 3, and 5) and cisplatin (60 mg/m2 on Days 1 and 2) every 21-28 days. One complete response and 14 partial responses were observed, with a median duration of response of 170 days and an overall median survival of 230 days. Toxicity was generally mild. Despite the high-dose cisplatin employed and the choice of patients with favorable prognostic factors in this study, results of this therapy remain disappointing.

Original languageEnglish
Pages (from-to)891-892
Number of pages2
JournalCancer Treatment Reports
Volume70
Issue number7
Publication statusPublished - 1986

Fingerprint

Etoposide
Cisplatin
Squamous Cell Carcinoma
Weight Loss
Outpatients
Neoplasm Metastasis
Survival
Brain
Therapeutics
Adenocarcinoma of lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ardizzoni, A., Canobbio, L., Pronzato, P., Rubagotti, A., De Palma, M., Baracco, F., ... Nosenzo, M. (1986). Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung. Cancer Treatment Reports, 70(7), 891-892.

Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung. / Ardizzoni, A.; Canobbio, L.; Pronzato, P.; Rubagotti, A.; De Palma, M.; Baracco, F.; Serrano, J.; Serrano, S.; Faravelli, B.; Nosenzo, M.

In: Cancer Treatment Reports, Vol. 70, No. 7, 1986, p. 891-892.

Research output: Contribution to journalArticle

Ardizzoni, A, Canobbio, L, Pronzato, P, Rubagotti, A, De Palma, M, Baracco, F, Serrano, J, Serrano, S, Faravelli, B & Nosenzo, M 1986, 'Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung', Cancer Treatment Reports, vol. 70, no. 7, pp. 891-892.
Ardizzoni, A. ; Canobbio, L. ; Pronzato, P. ; Rubagotti, A. ; De Palma, M. ; Baracco, F. ; Serrano, J. ; Serrano, S. ; Faravelli, B. ; Nosenzo, M. / Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung. In: Cancer Treatment Reports. 1986 ; Vol. 70, No. 7. pp. 891-892.
@article{02199e083fb044d3b32f261324dfc41d,
title = "Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung",
abstract = "Fifty patients with advanced squamous cell carcinoma and adenocarcinoma of the lung having good prognostic features (performance status ≤ 2; weight loss ≤ 10{\%}; and age ≤ 70 years; absence of brain metastases; and no prior treatment) were treated on an outpatient basis with etoposide (120 mg/m2 on Days 1, 3, and 5) and cisplatin (60 mg/m2 on Days 1 and 2) every 21-28 days. One complete response and 14 partial responses were observed, with a median duration of response of 170 days and an overall median survival of 230 days. Toxicity was generally mild. Despite the high-dose cisplatin employed and the choice of patients with favorable prognostic factors in this study, results of this therapy remain disappointing.",
author = "A. Ardizzoni and L. Canobbio and P. Pronzato and A. Rubagotti and {De Palma}, M. and F. Baracco and J. Serrano and S. Serrano and B. Faravelli and M. Nosenzo",
year = "1986",
language = "English",
volume = "70",
pages = "891--892",
journal = "Cancer Treatment Reports",
issn = "0361-5960",
publisher = "U.S. National Cancer Institute",
number = "7",

}

TY - JOUR

T1 - Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung

AU - Ardizzoni, A.

AU - Canobbio, L.

AU - Pronzato, P.

AU - Rubagotti, A.

AU - De Palma, M.

AU - Baracco, F.

AU - Serrano, J.

AU - Serrano, S.

AU - Faravelli, B.

AU - Nosenzo, M.

PY - 1986

Y1 - 1986

N2 - Fifty patients with advanced squamous cell carcinoma and adenocarcinoma of the lung having good prognostic features (performance status ≤ 2; weight loss ≤ 10%; and age ≤ 70 years; absence of brain metastases; and no prior treatment) were treated on an outpatient basis with etoposide (120 mg/m2 on Days 1, 3, and 5) and cisplatin (60 mg/m2 on Days 1 and 2) every 21-28 days. One complete response and 14 partial responses were observed, with a median duration of response of 170 days and an overall median survival of 230 days. Toxicity was generally mild. Despite the high-dose cisplatin employed and the choice of patients with favorable prognostic factors in this study, results of this therapy remain disappointing.

AB - Fifty patients with advanced squamous cell carcinoma and adenocarcinoma of the lung having good prognostic features (performance status ≤ 2; weight loss ≤ 10%; and age ≤ 70 years; absence of brain metastases; and no prior treatment) were treated on an outpatient basis with etoposide (120 mg/m2 on Days 1, 3, and 5) and cisplatin (60 mg/m2 on Days 1 and 2) every 21-28 days. One complete response and 14 partial responses were observed, with a median duration of response of 170 days and an overall median survival of 230 days. Toxicity was generally mild. Despite the high-dose cisplatin employed and the choice of patients with favorable prognostic factors in this study, results of this therapy remain disappointing.

UR - http://www.scopus.com/inward/record.url?scp=0022528737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022528737&partnerID=8YFLogxK

M3 - Article

C2 - 3719580

AN - SCOPUS:0022528737

VL - 70

SP - 891

EP - 892

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 7

ER -